



ASX Release

Anatara Gastrointestinal ReProgramming (GARP) dietary supplement – summary of preclinical studies

Highlights

- Successful preclinical program has provided strong scientific proof that Anatara's GaRP dietary supplement may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions
- GaRP has been shown to:
 - Address the dysbiosis of the microbiome
 - Reduce gut inflammation
 - Promote mucosal healing,
- GaRP has the potential to provide:
 - An adjuvant effect in reducing inflammation with the co-administration of disease-modifying medications
 - Dose reduction of disease-modifying medications known to have devastating side-effects
- GaRP does not affect the uptake or potential activity of probiotics

BRISBANE & MELBOURNE, 22nd January 2020: Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.

The Company remains highly encouraged by the successful *in vitro* and *in vivo* preclinical data reported for its GaRP dietary supplement to date, providing the Company with every confidence going into a human clinical study this year. Anatara believes its GaRP dietary supplement may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

During the preclinical development of the GaRP dietary supplement, the proprietary formulation has provided strong scientific evidence that it can combat the three underlying causes of chronic bowel conditions. In summary, GaRP:

- **Addressed the dysbiosis of the microbiome** by inhibiting the attachment and invasion of pro-inflammatory bacteria (obtained from IBD and IBS patients) into healthy gut cells by >95% (p=0.002).
- **Reduced gut inflammation** by 85% by significantly reducing the production of pro-inflammatory proteins, p<0.001). Daily treatment with GaRP demonstrated a therapeutic benefit by significantly reducing the key disease indicators of colitis in mice. When compared to a placebo control, GaRP reduced the combined disease characteristics of colon inflammation and disrupted bowel habits by 2.5-fold (p=0.012).

For personal use only

- **Promoted mucosal healing** by increasing mucin genes by a factor of 5 to 7-fold (MUC 2 and MUC6, $p < 0.001$). These genes have been shown to be significantly reduced in both IBD and IBS. Through increasing the genes, it is expected that the proteins which produce gut protecting and healing mucins will also increase which in turn may promote mucosal healing.

Anatara's GaRP dietary supplement has the potential to be used in a wide range of chronic gastrointestinal (GI) indications. As such, it was important that the Anatara team establish that the product would not interfere with the effectiveness of commonly used prescription medications indicated for GI disorders, as well as other commonly used complementary and alternative medicines, such as probiotics.

Anatara's preclinical data, as announced on 19th December 2019, suggests the co-administration of GaRP with a commonly used disease-modifying medication (these medications are the backbone of current IBD treatment regimens) demonstrated a significant increase in the reduction in inflammation.

GaRP administered in combination with 5-ASA, dexamethasone or prednisolone demonstrated increased the inhibition of IL-8 release from Caco-2 cells. All points reached statistical significance ($p < 0.05$, students t-test).

This is an exciting observation of an adjuvant effect and suggests the potential to significantly reduce the dose of relevant prescription medications. If this clinically-relevant finding translates into humans, patients will have the advantage of being able to reduce their dose of disease-modifying medications which are renowned for their devastating side-effects, such as sepsis. These findings are currently being confirmed in animal models of IBD.

Anatara also demonstrated that pre-treatment of probiotics with GaRP did not affect the efficacy of the probiotics. Pre-treatment of probiotics with GaRP, in all cases, did not significantly affect the attachment of the probiotics to the polarised Caco-2 enterocytes. In addition, the co-incubation of the probiotics with GaRP did not affect the efficacy of the probiotics, as determined by transepithelial electrical resistance (TEER) of polarised, inflamed Caco-2 cultures. These studies used *in vitro* gut models which are standard in the industry.

Anatara's Gastrointestinal ReProgramming (GaRP) dietary supplement

Anatara's GaRP dietary supplement is being developed to specifically target two human gastrointestinal disorders, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). IBS is the most common GI condition affecting approximately 11% of the global population¹ while IBD affects an estimated five million people globally²

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS³ and IBD⁴ patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients and healthcare providers believe the risk benefit of CAMs to be favourable, patients are willing to invest in their health, with this market segment being significant. In 2018, expenditure on gastrointestinal supplements and OTC digestive remedies in the US alone was US\$8 billion^{5,6}.

- ¹ Clinical Gastroenterology and Hepatology 2012: 10, 712-721.
² Crohn's and Colitis Australia.
³ Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.
⁴ Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712
⁵ Mintel's 2018 Digestive Health U.S., July 2019.
⁶ 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

For more information please contact:

Investor inquiries	Media inquiries
Steven Lydeamore CEO, Anataro Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataro.com	Sue MacLeman Chair, Anataro Lifesciences Ltd +61 (0) 437 211 200 smacleman@anataro.com

About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for animal and human health. Anataro is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataro Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.